To test whether lower immune infiltration might be a feature of TP53 mutant tumours beyond medulloblastoma and possibly in the context of sporadic TP53 mutations as well, we re-analysed a pan-cancer cohort of 8955 patients, again employing bulk deconvolution. The gene discussed is TP53; the disease is neoplasm.